Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices

CH Watson, L Soo, BA Davidson… - International Journal of …, 2020 - ijgc.bmj.com
Objective Limited information exists regarding risk reduction strategies for women with
moderate and low penetrance ovarian cancer susceptibility mutations. We sought to assess …

[PDF][PDF] Principal Investigator: Rebecca Previs, MD, MS

A Berchuck, B Davidson, J Eun, MMSL Havrilesky… - classic.clinicaltrials.gov
Genetic testing for hereditary cancer susceptibility gene mutations is a rapidly evolving
science, complicated both by an increasing awareness of its pertinence and the assumed …

The prevalence of germline mutations among patients with solid tumors with genomic alterations identified on tumor testing: Results from a tertiary care academic …

C Watson, S Tait, L Soo, JK Plichta, T Zhang… - 2020 - ascopubs.org
1516 Background: The proportion of germline versus somatic mutations identified on
genomic tumor testing of solid malignancies is not well characterized. We compared somatic …